Dramatic Response to Lorlatinib in a Patient With

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

5 citing papers in PubMed, 8 citations in OpenAlex.

1. Repotrectinib Overcomes F2004V Resistance Mutation inJTO clinical and research reports · 2023
   Article
2. NVL-520 Is a Selective, TRK-Sparing, and Brain-Penetrant Inhibitor of ROS1 Fusions and Secondary Resistance Mutations.Cancer discovery · 2023
   Article
3. Resistance Profile and Structural Modeling of Next-Generation ROS1 Tyrosine Kinase Inhibitors.Molecular cancer therapeutics · 2022
   Article
4. Short-term response to immune-chemotherapy and immune features of a ceritinib-resistant patient withJournal for immunotherapy of cancer · 2021
   Article
5. Entrectinib Response to ROS1-Fusion-Positive Non-Small-Cell Lung Cancer That Progressed on Crizotinib with Leptomeningeal Metastasis: A Case Report.Case reports in oncology
   Article

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

3 authors at 2 institutions in 1 country.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.